





Are single-condition single-drug trials ecologically valid in the field of pain?

SASP 2019

04.04.2019


Eija Kalso, MD, PhD
Pain Clinic, Helsinki University and Helsinki University Hospital


#### Potential conflicts of interest

- advisory board memberships:
  - Orion Pharma
  - Pierre Fabre
- working environment: critical

### My arguments are that:


- Pain is rarely a single condition
- Analgesic monotherapy is rarely a solution to chronic pain






# Multidisciplinary pain management is the gold standard


- one or several analgesics
- · other drugs
- +
- education
- pscyhological interventions
- physiotherapy








### **Analgesics**


- Work well in some but not in others
- Analgesics can work in different conditions




















## More individualized studies:

identifying subgroups tailoring treatments

- patients have special resources/problems
- different pain phenotypes and comorbidities
- patients have (pharmaco)genetic differences
- · identifying subgroups for
  - tailored treatments as part of clinical work providing data for future research
  - for internet-based interventions and research
- · single case studies

